Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.46 |
| ▸ | STS | P08842 | 7/20 | 0.45 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928327 | 0.83 | STS (0.65) | CA12CA1CA2CA9CA14 | |
| SCHEMBL23072877 | 0.83 | CA1 (0.54) | CA12CA1CA2CA9CA14 | |
| SCHEMBL28433059 | 0.81 | CXCR2 (0.46) | CA1CA2CXCR2STSCXCR1 | |
| SCHEMBL1713127 | 0.80 | STS (0.62) | CA12CA1CA2CA9CXCR2 | |
| SCHEMBL2188550 | 0.79 | STS (0.59) | CA12CA1CA2CA9CA14 | |
| SCHEMBL6132404 | 0.79 | STS (0.59) | CA12CA1CA2CA9CA14 | |
| SCHEMBL14720856 | 0.79 | STS (0.68) | CA12CA1CA2CA9CA14 | |
| SCHEMBL840762 | 0.79 | KMT2A (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL3668194 | 0.79 | STS (0.60) | CXCR2STSCXCR1ELANEHSD11B1 | |
| SCHEMBL109451 | 0.78 | CA1 (0.61) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432700-B1 | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7078420-B2 | Spiro-hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| US-6977267-B2 | Spiro-hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050004153-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | DHAR T G MURALI (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040259897-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | DHAR T G MURALI (US) | 2004-12-23 | — | — | US | disclosed |
| EP-1432700-A4 | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040248920-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | DHAR T G MURALI (US) | 2004-12-09 | — | — | US | disclosed |
| EP-1432700-A1 | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | Bristol-Myers Squibb Company (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040009998-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | CEREP SA (FR) | 2004-01-15 | — | — | US | disclosed |
| WO-2003029245-A1 | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259897-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | ICAM1, VCAM1, SELL | CA12 4019/4885CA1 1930/4885CA2 2814/4885 |
| US-20040248920-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | ICAM1, VCAM1, SELL | CA12 4019/4885CA1 1930/4885CA2 2814/4885 |
| US-20040009998-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | ICAM1, VCAM1, SELL | CA12 4024/4885CA1 1972/4885CA2 2829/4885 |
| US-20050004153-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | ICAM1, VCAM1, ITGA4 | CA12 3408/4885CA1 1712/4885CA2 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.